Inhibikase治疗技术公司在各种分析师意见不一的情况下获得了强劲的买价升级,其库存因数量增加而增至1.54美元。 Inhibikase Therapeutics got a strong-buy upgrade amid mixed analyst views, with its stock rising to $1.54 on increased volume.

Inhibikase治疗学(IKT)得到Cantor Fitzgerald的“强购”评级升级,与其他公司一道表示乐观,尽管分析师的看法不一。 Inhibikase Therapeutics (IKT) received a “strong-buy” rating upgrade from Cantor Fitzgerald, joining other firms in expressing optimism despite mixed analyst views. 该公司开发帕金森病及相关病症的治疗方法,正在推进IkT-18009神经和胃肠症状和癌症的IkT-001Pro。 The company, developing treatments for Parkinson’s disease and related conditions, is advancing IkT-148009 for neurological and gastrointestinal symptoms and IkT-001Pro for cancer. 股票在星期四涨至1.54美元,数额高于平均数额,市场上限为1.1578亿美元,并报告11月14日收入中每股损失1.3美元。 The stock rose to $1.54 on Thursday with above-average volume, has a market cap of $115.78 million, and reported a loss of $0.13 per share in its November 14 earnings.